Innovent Biologics, Inc. (IVBIY)
OTCMKTS · Delayed Price · Currency is USD
39.75
0.00 (0.00%)
At close: Jan 29, 2026
Innovent Biologics Revenue
Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.
Revenue (ttm)
11.42B CNY
Revenue Growth
+53.18%
P/S Ratio
12.48
Revenue / Employee
1.85M CNY
Employees
6,190
Market Cap
19.90B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
| Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
| Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
| Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
| Dec 31, 2020 | 3.84B | 2.80B | 266.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
Innovent Biologics News
- 3 days ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 3 days ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 2 months ago - ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma - PRNewsWire
- 2 months ago - Innovent Biologics Enters Hang Seng Index and Two Other Major Indices; Global Capital Markets Recognize Leading Innovator's Value - PRNewsWire
- 3 months ago - Mazdutide 9 mg Achieves Up to 20.1% Weight Loss in Chinese Adults with Obesity, GLORY-2 Study Meets Primary and All Key Secondary Endpoints - PRNewsWire